<DOC>
	<DOCNO>NCT02283294</DOCNO>
	<brief_summary>The purpose study evaluate Apixaban decrease complication another stroke people atrial fibrillation initiate earlier standard care .</brief_summary>
	<brief_title>Apixaban Early Prevention Recurrent Embolic Stroke Hemorrhagic Transformation</brief_title>
	<detailed_description>This Open label , randomize , active control , parallel-group pilot trial examine effect initiation APIXABAN day 0-3 ( TIA ) , day 3-5 ( small stroke ) day 7-9 ( medium stroke ) decrease fatal and/or recurrent stroke/TIA 120 subject suffer recent ( 0 48 hour symptom ) TIA , small medium ischemic stroke compare standard care warfarin treatment regimen . Subjects randomly assign 1:1 ratio one two treatment arm ( apixaban warfarin ) . Subjects follow total 180 day screen monthly follow-up visit .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Signed Written Informed Consent 2 . Males Females 18 year age . 3 . History Nonvalvular Atrial Fibrillation ( NVAF ) documentation medical history newly diagnose nonvalvular Atrial Fibrillation time study randomization ECG , device telemetry . 4 . Diagnosis TIA small medium ischemic stroke 0 48 hour sign symptom . 5 . Women childbearing potential must use reliable method contraception must provide negative pregnancy test entry study within 24 hour study treatment initiation . 6 . WOCBP must agree follow instruction method ( ) contraception duration treatment study drug Apixaban plus 5 halflives ( approximately 3 day ) plus 30 day ( duration ovulatory cycle ) total 33 day posttreatment completion . 7 . Males sexually active WOCBP must agree follow instruction method ( ) contraception duration treatment Apixaban plus 5 halflives ( approximately 3 day ) plus 90 day ( duration sperm turnover ) total 93 day posttreatment completion . 8 . Azoospermic male WOCBP continuously heterosexually active exempt contraceptive requirement . However must still undergo pregnancy test described section . Investigators shall counsel WOCBP male subject sexually active WOCBP importance pregnancy prevention implication unexpected pregnancy Investigators shall advise WOCBP male subject sexually active WOCBP use highly effective method contraception . Highly effective method contraception failure rate &lt; 1 % use consistently correctly . At minimum , subject must agree use one method highly effective contraception list : HIGHLY EFFECTIVE METHODS OF CONTRACEPTION Male condom spermicide Hormonal method contraception include combined oral contraceptive pill , vaginal ring , injectables , implant intrauterine device ( IUDs ) Mirena WOCBP subject male subject 's WOCBP partner . Female partner male subject participate study may use hormone base contraceptives one acceptable method contraception since receive study drug IUDs , ParaGardâ„¢ Tubal ligation Vasectomy . Complete Abstinence 1 . Hemorrhagic stroke 2 . Large ischemic stroke 3 . History major bleeding within last 6 month time subject enrollment ( e.g . GI bleed ) 4 . History intracranial bleed a. Traumatic intracranial bleed within one year randomization . ( Traumatic ICH great one year randomization exclusion ) . 5 . Current history bleeding disorder ( e.g . blood dyscrasia ) 6 . Blood Pressure 180/100 mmHg hypertensive therapy day randomization per PI discretion . 7 . Current illicit drug use and/or chronic alcohol use per PI discretion . 8 . Severe liver disease ( AST/ALT 2x upper limit ) . 9 . Patients kidney disease meeting criterion take 2.5 mg twice daily take strong dual inhibitor CYP3A4 Pglycoprotein ( e.g . ketoconazole , itraconazole , ritonavir , clarithromycin ) . 10 . Any suspected etiology stroke ( e.g . ipsilateral carotid disease ) . 11 . Greater 3 Cerebral Microbleeds ( CMB ) gradient recovery echo ( GRE ) evidence intracranial hemorrhage CT time randomization . ( SWI sequencing may use GRE sequence obtainable . 12 . Therapeutically anticoagulated time admission ( INR admission great 2.0 warfarin take two consecutive dos NOAC . 13 . Absolute indication use warfarin . ( e.g . Mechanical Valve ) 14 . Absolute indication anticoagulation prior randomization window . ( e.g . DVT ) 15 . Hemoglobin le 9 gm/dl and/or platelet count le 100 K/uL . 16 . Requires dual antiplatelet therapy . 17 . Daily use NSAIDS 18 . Pregnancy lactation . 19 . Any use investigational product within past 30 day . 20 . Prisoners subject involuntarily incarcerate . 21 . Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness . 22 . Concurrent participation another clinical study use investigational product use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>